XFOR - NASDAQ

X4 Pharmaceuticals, Inc.

XFOR·NASDAQ

$4.08

+0.99%

HealthcareBiotechnology

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$384.82M

EPS-1.8700

P/E Ratio-2.18

Earnings Date08/06/2026

290.46M

Assets

98%

3Y+87.0%

5Y+136.0%

10Y+3720.0%

104.17M

Total Liabilities

-16%

3Y+28.0%

5Y+108.0%

10Y+62.0%

186.29M

Total Equity

741%

3Y+152.0%

5Y+156.0%

10Y-429.0%

X4 Pharmaceuticals, Inc. Funding & Solvency Profile

XFOR · NASDAQ

Current Assets

Cash & Cash Equivalents217.05M

Net Receivables573.00K

Inventory4.48M

Other Current Assets3.53M

Total Current Assets262 M

Non-Current Assets

Property, Plant & Equipment1.59M

Goodwill & Intangible Assets26.60M

Long-Term Investments0.00

Other Non-Current Assets692.00K

Total Non-Current Assets2 M

Total Assets

290.46M

Financial Health Analysis

Current Ratio

10.16x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.56x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

236 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

90% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

X4 Pharmaceuticals, Inc. Balance Sheet

XFOR • NASDAQ

X4 Pharmaceuticals, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	217M	55.7M	99.2M	121.7M	81.8M	78.7M	126.2M	30.8M	76.8M	3M	6.8M
Short-Term Investments	35.9M	46.4M	15M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	253M	102.1M	114.2M	121.7M	81.8M	78.7M	126.2M	30.8M	76.8M	3M	6.8M
Net Receivables	573K	1.7M	562K	1.2M	747K	917K	2M	2.9M	1.6M	1.3M	1.5M
Accounts Receivables	573K	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	1.6M	1.3M	1.5M
Other Receivables	0.0	640K	562K	1.2M	747K	917K	2M	2.9M	0.0	0.0	0.0
Inventory	4.5M	2.8M	0.0	0.0	0.0	0.0	0.0	0.0	355K	1.2M	0.0
Prepaids	0.0	0.0	0.0	0.0	0.0	3.7M	1.1M	1.4M	1.1M	1.3M	87K
Other Current Assets	3.5M	5.6M	7.3M	5.8M	5.3M	0.0	0.0	101K	0.0	0.0	0.0
Total Current Assets	261.6M	112.2M	122.1M	128.7M	87.9M	83.3M	129.3M	35.1M	80.8M	5.7M	8.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	1.6M	4.8M	6.4M	8.3M	10.2M	9.2M	2.4M	285K	421K	519K	760K
Goodwill	17.4M	17.4M	17.4M	17.4M	17.4M	27.1M	27.1M	0.0	0.0	0.0	0.0
Intangible Assets	9.3M	10M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	26.6M	27.4M	17.4M	17.4M	17.4M	27.1M	27.1M	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	1.3M	0.0	0.0	364K	355K	394K	338K
Other Non-Current Assets	692K	2.1M	1.4M	1.2M	402K	3.3M	1.9M	275K	-355K	975K	25K
Total Non-Current Assets	28.9M	34.3M	25.2M	26.9M	29.3M	39.6M	31.4M	924K	421K	1.9M	1.1M
Total Assets	290.5M	146.4M	147.3M	155.6M	117.2M	122.9M	160.7M	36M	81.3M	7.6M	9.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.7M	8.6M	8.9M	7.8M	4.3M	3.1M	2.1M	545K	1.9M	1.6M	423K
Accounts Payable	5.7M	8.6M	8.9M	7.8M	4.3M	3.1M	2.1M	545K	1.9M	1.6M	423K
Accrued Expenses	14.3M	10M	4.6M	5.4M	5.4M	4.3M	3.5M	924K	2.5M	1.3M	949K
Short Term Debt	0.0	0.0	0.0	1.3M	1.9M	0.0	0.0	1.7M	2.3M	5.1M	2.5M
Capital Lease Obligations (Current)	994K	1.3M	1.1M	1.2M	0.0	786K	898K	0.0	0.0	-1.6M	-423K
Deferred Revenue	464K	0.0	0.0	0.0	0.0	0.0	0.0	737K	2.6M	504K	430K
Other Current Liabilities	4.3M	13.1M	8.2M	6.6M	2.5M	3.8M	2.9M	1.5M	3.3M	3.5M	2.4M
Total Current Liabilities	25.8M	32.9M	22.9M	22.3M	14M	11.9M	9.4M	5.4M	7.7M	12.1M	6.7M
NON-CURRENT LIABILITIES
Long Term Debt	76.3M	75.4M	54.6M	32.3M	33.1M	33.2M	20.1M	7.9M	9.9M	10.1M	4.7M
Deferred Revenue (Non-Current)	621K	0.0	0.0	0.0	0.0	0.0	0.0	1.1M	2.6M	2.1M	2.4M
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9K	39.8M	29.9M
Other Non-Current Liabilities	1.5M	14.6M	16.1M	23.3M	826K	462K	16K	5K	9K	-39.8M	-29.9M
Total Non-Current Liabilities	78.4M	91.4M	73.3M	59.2M	38.7M	38.1M	22M	9M	14.9M	52.1M	37.2M
Capital Lease Obligations	994K	2.7M	3.7M	4.8M	4.8M	5.3M	2.8M	0.0	0.0	0.0	0.0
Total Liabilities	104.2M	124.3M	96.2M	81.5M	52.8M	50.1M	31.5M	14.4M	22.5M	64.2M	43.8M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-371K
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	65.4M	81.3M	39.8M	29.9M
Common Stock	91K	6K	167K	122K	28K	16K	16K	15K	15K	1K	1K
Additional Paid-In Capital	780.9M	537.6M	529M	450.8M	347.4M	267.1M	261.4M	156.6M	150.8M	880K	371K
Retained Earnings	-594.6M	-515.4M	-477.9M	-376.7M	-282.9M	-194.2M	-132M	-135.3M	-92.3M	-58.4M	-35.4M
Accumulated Other Comprehensive Income/Loss	-109K	-122K	-119K	-119K	-119K	-119K	-119K	241K	127K	834K	718K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	39.9M	-29.9M
Total Stockholders' Equity	186.3M	22.1M	51.1M	74.1M	64.4M	72.8M	129.2M	21.6M	58.7M	-56.6M	-34.3M
Total Equity	186.3M	22.1M	51.1M	74.1M	64.4M	72.8M	129.2M	21.6M	58.7M	-56.6M	-34.3M
SUMMARY
Total Liabilities & Equity	290.5M	146.4M	147.3M	155.6M	117.2M	122.9M	160.7M	36M	81.3M	7.6M	9.5M
Total Investments	35.9M	46.4M	15M	0.0	1.3M	0.0	0.0	364K	355K	394K	338K
Total Debt	77.3M	78.1M	58.3M	38.4M	39.8M	38.4M	22.9M	7.9M	12.2M	15.3M	7.2M
Net Debt	-139.8M	22.4M	-40.9M	-83.3M	-42M	-40.3M	-103.3M	-22.9M	-64.6M	12.3M	435K
Shares Outstanding	11,408,300	11,408,300	11,408,300	11,408,300	11,408,300	11,408,300	11,408,300	11,408,300	11,408,300	11,408,300	11,408,300

SEC Filings

XFOR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K/A 8-K/A 2026 (Amended) N/A	May 13, 2026	May 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 11, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
S-3 S-3 N/A	May 06, 2026	May 06, 2026		View Filing
DEF 14A DEF 14A 2026 N/A	March 20, 2026	March 20, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 17, 2026	December 31, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 05, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 05, 2025	November 05, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 27, 2025	October 23, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 17, 2025	September 15, 2025	2025	View Filing

Showing 1 to 10 of 206 filings

Related Guides

Blog Categories

Continue your XFOR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.